Korro Bio (KRRO) Receivables (2018 - 2025)
Korro Bio's (KRRO) quarterly Receivables came in at $969000.0 in Q4 2025, down 42.87% YoY from $1.7 million in Q4 2024, and up 18.17% on a QoQ basis from $820000.0 in Q3 2025.
Korro Bio (KRRO) Receivables (2018 - 2025) Analysis & Trends
Korro Bio (KRRO) has 5 years of Receivables data on file, last reported at $969000.0 in Q4 2025.
- Quarterly Receivables fell 42.87% year-over-year to $969000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $969000.0 (down 42.87% YoY) and the FY2025 annual result came in at $1.0 million, down 41.18% from the prior year.
- Receivables climbed to $969000.0 in Q4 2025, from $820000.0 in the prior quarter.
- In the past five years, Receivables ranged from a high of $10.0 million in Q3 2024 to a low of $820000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.41 Bn | 130.56 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.41 Bn | 59.23 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 57.56 Bn | 52.43 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 42.06 Bn | 36.96 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 30.95 Bn | 27.65 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 27.48 Bn | 9.09 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.31 Bn | 26.15 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.04 Bn | 26.20 Bn | - | - |
| 10 | Korro Bio | 229.39 Mn | 114.36 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 969,000.00 |
| Sep 30, 2025 | 820,000.00 |
| Jun 30, 2025 | 1.10 Mn |
| Mar 31, 2025 | 1.92 Mn |
| Dec 31, 2024 | 1.70 Mn |
| Sep 30, 2024 | 10.00 Mn |
| Mar 31, 2020 | 246,000.00 |
| Dec 31, 2019 | 805,000.00 |
| Sep 30, 2019 | 408,000.00 |
| Dec 31, 2018 | 161,000.00 |